It has been reported that NAT10 is a possible clinical target for a variety of progressive diseases, including cancer and Hutchinson-Gilford-Progeria syndrome (HGPS) 29,30. This evidence concerns the gene NAT10 and Hutchinson-Gilford progeria syndrome.